Alcohol Consumption and Risk of Liver Fibrosis in People Living With HIV: A Systematic Review and Meta-Analysis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Apr 4

PMID 35371091

Authors

Hang Lyu

Haotong Tang

Yizhi Liang

Shaoli Huang

Yuyu Wang

Wenyan Huang

Yi Zhou

Affiliations

Soon will be listed here.

Abstract

Objectives: It is unclear if a high level of alcohol consumption is a risk factor for liver fibrosis for people living with HIV (PLWH). This study systematically summarizes the risk relationship between different alcohol consumption and the incidence of liver fibrosis among PLWH.

Methods: We identified potential studies by searching the PubMed, Embase, Web of Science Library, and CNKI databases up to September 26th, 2021. Observation studies in PLWH that evaluated the relationship between alcohol consumption and the risk of liver fibrosis and estimated the effect of alcohol with pooled odds ratios (pooled ORs) and 95% confidence intervals (CIs) were included.

Results: There were total 15 studies included in data analysis. Three studies were set up as cohort studies and the other twelve were cross-sectional studies. Our study was based on 22,676 individuals and 2,729 liver fibrosis cases from 15 studies. Alcohol abuse is a significant risk factor of liver fibrosis (pooled OR = 2.25, 95% CI: 1.59-3.17, p < 0.05) among PLWH. Daily alcohol consumption > 50 g can elevate the risk of liver fibrosis (pooled OR = 3.10, 95% CI: 2.02-4.73, p < 0.05) among PLWH. However, high-risk alcohol consumption determined by AUDIT-C (AUDIT-C ≥ 4) had little or no effect on subsequent liver fibrosis risk. Further, alcohol consumption > 50 g is also a risk factor to liver fibrosis in PLWH co-infected with HCV (pooled OR = 2.48, 95% CI: 1.62-3.80, p < 0.05) and in HIV mono-infected (pooled OR = 1.85, 95% CI: 1.00-3.43, p < 0.05).

Conclusion: Alcohol consumption is associated with an increased risk of liver fibrosis in PLWH. HCV co-infection with alcohol abuse could possibly induce a higher risk of liver fibrosis than HIV mono-infected patients.

Systematic Review Registration: PROSPERO, identifier (CRD42021272604).

Citing Articles

HPV-associated cancers among people living with HIV: nationwide population-based retrospective cohort study 2004-21 in Estonia.

Tisler A, Toompere K, Bardou M, Diaz J, Orumaa M, Uuskula A Eur J Public Health. 2024; 34(6):1199-1204.

PMID: 39378418 PMC: 11631392. DOI: 10.1093/eurpub/ckae152.

Increased Intestinal Permeability and Decreased Resiliency of the Intestinal Barrier in Alcoholic Liver Disease.

Swanson G, Garg K, Shaikh M, Keshavarzian A Clin Transl Gastroenterol. 2024; 15(4):e00689.

PMID: 38334953 PMC: 11042778. DOI: 10.14309/ctg.0000000000000689.

Liver Transplantation in People Living with HIV: Still an Experimental Procedure or Standard of Care?.

Lynch E, Russo F Life (Basel). 2023; 13(10).

PMID: 37895356 PMC: 10608432. DOI: 10.3390/life13101975.

Association of alcohol use and multimorbidity among adults aged 40 years and above in rural South Africa.

Mpinganjira M, Chirwa T, Kabudula C, Gomez-Olive F, Tollman S, Francis J Sci Rep. 2023; 13(1):7807.

PMID: 37183234 PMC: 10183457. DOI: 10.1038/s41598-023-35018-6.

Hepatocyte-Specific Triggering of Hepatic Stellate Cell Profibrotic Activation by Apoptotic Bodies: The Role of Hepatoma-Derived Growth Factor, HIV, and Ethanol.

New-Aaron M, Koganti S, Ganesan M, Kanika S, Kumar V, Wang W Int J Mol Sci. 2023; 24(6).

PMID: 36982417 PMC: 10049507. DOI: 10.3390/ijms24065346.

References

Carton J, Collazos J, de la Fuente B, Asensi V . Course of liver fibrosis in HIV-hepatitis C virus-coinfected patients depending on the response to hepatitis C therapy. AIDS Res Hum Retroviruses. 2012; 29(2):215-22. DOI: 10.1089/AID.2012.0108. View

Schiavini M, Angeli E, Mainini A, Zerbi P, Duca P, Gubertini G . Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002. HIV Med. 2006; 7(5):331-7. DOI: 10.1111/j.1468-1293.2006.00384.x. View

Sanchez-Roige S, Palmer A, Clarke T . Recent Efforts to Dissect the Genetic Basis of Alcohol Use and Abuse. Biol Psychiatry. 2019; 87(7):609-618. PMC: 7071963. DOI: 10.1016/j.biopsych.2019.09.011. View

Merchante N, Perez-Camacho I, Mira J, Rivero A, Macias J, Camacho A . Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. Antivir Ther. 2010; 15(5):753-63. DOI: 10.3851/IMP1612. View

Pavlov C, Casazza G, Nikolova D, Tsochatzis E, Burroughs A, Ivashkin V . Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev. 2015; 1:CD010542. PMC: 7081746. DOI: 10.1002/14651858.CD010542.pub2. View

Jaquet A, Wandeler G, Nouaman M, Ekouevi D, Tine J, Patassi A . Alcohol use, viral hepatitis and liver fibrosis among HIV-positive persons in West Africa: a cross-sectional study. J Int AIDS Soc. 2017; 19(1):21424. PMC: 5467604. DOI: 10.7448/IAS.20.1.21424. View

Vermehren J, Vermehren A, Mueller A, Carlebach A, Lutz T, Gute P . Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers. BMC Gastroenterol. 2012; 12:27. PMC: 3361499. DOI: 10.1186/1471-230X-12-27. View

Saunders J, Aasland O, Babor T, De la Fuente J, Grant M . Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction. 1993; 88(6):791-804. DOI: 10.1111/j.1360-0443.1993.tb02093.x. View

Kisseleva T, Brenner D . Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2020; 18(3):151-166. DOI: 10.1038/s41575-020-00372-7. View

10.

Castera L . Assessing liver fibrosis. Expert Rev Gastroenterol Hepatol. 2008; 2(4):541-52. DOI: 10.1586/17474124.2.4.541. View

11.

Ferguson T, Rosen E, Carr R, Brashear M, Simon L, Theall K . Associations of Liver Disease with Alcohol Use among People Living with HIV and the Role of Hepatitis C: The New Orleans Alcohol Use in HIV Study. Alcohol Alcohol. 2019; 55(1):28-36. PMC: 7005833. DOI: 10.1093/alcalc/agz089. View

12.

Shubber Z, Mills E, Nachega J, Vreeman R, Freitas M, Bock P . Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis. PLoS Med. 2016; 13(11):e1002183. PMC: 5127502. DOI: 10.1371/journal.pmed.1002183. View

13.

Pandrea I, Happel K, Amedee A, Bagby G, Nelson S . Alcohol's role in HIV transmission and disease progression. Alcohol Res Health. 2013; 33(3):203-18. PMC: 3860502. View

14.

Dhanda A, Collins P . Immune dysfunction in acute alcoholic hepatitis. World J Gastroenterol. 2015; 21(42):11904-13. PMC: 4641112. DOI: 10.3748/wjg.v21.i42.11904. View

15.

Bagby G, Amedee A, Siggins R, Molina P, Nelson S, Veazey R . Alcohol and HIV Effects on the Immune System. Alcohol Res. 2015; 37(2):287-97. PMC: 4590624. View

16.

Lim J, Tate J, Fultz S, Goulet J, Conigliaro J, Bryant K . Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis. 2014; 58(10):1449-58. PMC: 4001286. DOI: 10.1093/cid/ciu097. View

17.

OKeefe J, Bhatti S, Bajwa A, DiNicolantonio J, Lavie C . Alcohol and cardiovascular health: the dose makes the poison…or the remedy. Mayo Clin Proc. 2014; 89(3):382-93. DOI: 10.1016/j.mayocp.2013.11.005. View

18.

Hernandez-Gea V, Friedman S . Pathogenesis of liver fibrosis. Annu Rev Pathol. 2010; 6:425-56. DOI: 10.1146/annurev-pathol-011110-130246. View

19.

Yaya I, Roux P, Marcellin F, Wittkop L, Esterle L, Spire B . Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients. PLoS One. 2018; 13(7):e0199874. PMC: 6033422. DOI: 10.1371/journal.pone.0199874. View

20.

Macias J, Castellano V, Merchante N, Palacios R, Mira J, Saez C . Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS. 2004; 18(5):767-74. DOI: 10.1097/00002030-200403260-00007. View